TrialDiabetes, obesity & metabolism2022

Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.

Søren Snitker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.